BTIG Research downgraded shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) from a buy rating to a neutral rating in a research report sent to investors on Wednesday morning.

Other research analysts have also recently issued research reports about the company. Guggenheim reiterated a buy rating and issued a $80.00 price target on shares of Teva Pharmaceutical Industries in a research note on Monday, August 15th. Mizuho restated a buy rating and set a $70.00 price objective (down previously from $75.00) on shares of Teva Pharmaceutical Industries in a research note on Friday, August 5th. Jefferies Group restated a buy rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, August 3rd. Morgan Stanley set a $63.00 price objective on Teva Pharmaceutical Industries and gave the company a buy rating in a research note on Monday, September 12th. Finally, RBC Capital Markets set a $71.00 price objective on Teva Pharmaceutical Industries and gave the company a buy rating in a research note on Sunday, September 11th. Thirteen research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. Teva Pharmaceutical Industries presently has a consensus rating of Buy and an average target price of $60.00.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Shares of Teva Pharmaceutical Industries (NYSE:TEVA) traded up 3.26% on Wednesday, hitting $39.31. The company’s stock had a trading volume of 4,680,456 shares. The company has a 50 day moving average of $42.97 and a 200 day moving average of $49.87. Teva Pharmaceutical Industries has a 1-year low of $37.25 and a 1-year high of $66.55. The firm has a market cap of $35.93 billion, a PE ratio of 26.26 and a beta of 0.73.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Tuesday, November 15th. The company reported $1.31 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.29 by $0.02. Teva Pharmaceutical Industries had a return on equity of 17.77% and a net margin of 7.56%. The business had revenue of $5.56 billion for the quarter, compared to analysts’ expectations of $5.71 billion. During the same quarter in the previous year, the firm posted $1.35 earnings per share. The company’s revenue was up 15.3% compared to the same quarter last year. Equities analysts forecast that Teva Pharmaceutical Industries will post $5.16 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 20th. Shareholders of record on Monday, December 5th will be paid a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 3.57%. Teva Pharmaceutical Industries’s dividend payout ratio is 58.39%.

Hedge funds have recently bought and sold shares of the company. Sharkey Howes & Javer raised its stake in Teva Pharmaceutical Industries by 21.7% in the second quarter. Sharkey Howes & Javer now owns 2,008 shares of the company’s stock valued at $101,000 after buying an additional 358 shares during the last quarter. Hudock Capital Group LLC raised its stake in shares of Teva Pharmaceutical Industries by 37.6% in the second quarter. Hudock Capital Group LLC now owns 2,064 shares of the company’s stock worth $103,000 after buying an additional 564 shares in the last quarter. Washington Trust Bank raised its stake in shares of Teva Pharmaceutical Industries by 2.7% in the third quarter. Washington Trust Bank now owns 2,232 shares of the company’s stock worth $103,000 after buying an additional 58 shares in the last quarter. WFG Advisors LP raised its stake in shares of Teva Pharmaceutical Industries by 14.0% in the second quarter. WFG Advisors LP now owns 2,080 shares of the company’s stock worth $104,000 after buying an additional 256 shares in the last quarter. Finally, Kistler Tiffany Companies LLC raised its stake in shares of Teva Pharmaceutical Industries by 3.1% in the second quarter. Kistler Tiffany Companies LLC now owns 2,135 shares of the company’s stock worth $107,000 after buying an additional 64 shares in the last quarter. 63.00% of the stock is owned by institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.

5 Day Chart for NYSE:TEVA

Receive News & Stock Ratings for Teva Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd. and related stocks with our FREE daily email newsletter.